Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
53 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Crucell N.V. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Crucell N.V. - Product Pipeline Review - 2014', provides an overview of the Crucell N.V.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Crucell N.V.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Crucell N.V. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Crucell N.V.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Crucell N.V.'s pipeline products Reasons to buy - Evaluate Crucell N.V.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Crucell N.V. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Crucell N.V.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Crucell N.V. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Crucell N.V. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Crucell N.V. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Crucell N.V. Snapshot 6 Crucell N.V. Overview 6 Key Information 6 Key Facts 6 Crucell N.V. - Research and Development Overview 7 Key Therapeutic Areas 7 Crucell N.V. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Crucell N.V. - Pipeline Products Glance 14 Crucell N.V. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Crucell N.V. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Discovery Products/Combination Treatment Modalities 17 Crucell N.V. - Drug Profiles 18 Ad35-CS 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 CL-184 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 CR-8020 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Crucell Ad-35 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 FluCell 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 diridavumab 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 rAd5HVR48 HIV-1 Vaccine 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Vaccine for Multivalent Filovirus 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Antibodies for Hepatitis C 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 CR-8033 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 CR-8043 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 CR-8071 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 CR-9114 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Flu-mAb 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Vaccine for Human Papillomavirus 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Vaccine for Respiratory Syncytial Virus (RSV) Infections 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Vaccines for Infectious Diseases 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Crucell N.V. - Pipeline Analysis 40 Crucell N.V. - Pipeline Products by Target 40 Crucell N.V. - Pipeline Products by Route of Administration 42 Crucell N.V. - Pipeline Products by Molecule Type 43 Crucell N.V. - Pipeline Products by Mechanism of Action 44 Crucell N.V. - Recent Pipeline Updates 45 Crucell N.V. - Dormant Projects 47 Crucell N.V. - Company Statement 48 Crucell N.V. - Locations And Subsidiaries 49 Head Office 49 Other Locations & Subsidiaries 49 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 53 Disclaimer 53
List of Tables Crucell N.V., Key Information 6 Crucell N.V., Key Facts 6 Crucell N.V. - Pipeline by Indication, 2014 9 Crucell N.V. - Pipeline by Stage of Development, 2014 10 Crucell N.V. - Monotherapy Products in Pipeline, 2014 11 Crucell N.V. - Partnered Products in Pipeline, 2014 12 Crucell N.V. - Partnered Products/ Combination Treatment Modalities, 2014 13 Crucell N.V. - Phase II, 2014 14 Crucell N.V. - Phase I, 2014 15 Crucell N.V. - Preclinical, 2014 16 Crucell N.V. - Discovery, 2014 17 Crucell N.V. - Pipeline by Target, 2014 41 Crucell N.V. - Pipeline by Route of Administration, 2014 42 Crucell N.V. - Pipeline by Molecule Type, 2014 43 Crucell N.V. - Pipeline Products by Mechanism of Action, 2014 44 Crucell N.V. - Recent Pipeline Updates, 2014 45 Crucell N.V. - Dormant Developmental Projects,2014 47 Crucell N.V., Other Locations 49 Crucell N.V., Subsidiaries 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
